NF449, a novel picomolar potency antagonist at human P2X1 receptors.
about
The h-P2X3 glycoprotein receptor as an example of integrating bioinformatics and structural research.Vascular smooth muscle cells from small human omental arteries express P2X1 and P2X4 receptor subunits.Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2.Activation and regulation of purinergic P2X receptor channelsPilot-scale compound screening against RNA editing identifies trypanocidal agents.The impact of commercially available purinergic ligands on purinergic signalling research.Exposure to an Extremely-Low-Frequency Magnetic Field Stimulates Adrenal Steroidogenesis via Inhibition of Phosphodiesterase Activity in a Mouse Adrenal Cell LineP2X1 receptor-mediated inhibition of the proliferation of human coronary smooth muscle cells involving the transcription factor NR4A1The P2X1 ion channel in platelet function.The P2X1 receptor and platelet function.Ectodomain lysines and suramin block of P2X1 receptors.Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop.Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.Purinoreceptor-mediated current in myocytes from renal resistance arteries.P2X receptor chimeras highlight roles of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desensitization, and independent regulation of channel transitions
P2860
Q30428280-63FC8824-DB24-4185-9F49-8BB49542F8FAQ34744913-79301E25-FA97-4B79-A0B1-5143D5CF6E4CQ35114405-29A8D88E-EB0B-4456-8518-53F9AA9CF8CBQ35122793-2D602CD8-42D3-418A-9B21-0E7A6D3598CEQ35234642-D10EFB1F-2224-4A72-96B1-C2CD3694E5CFQ35693550-518F85E9-695C-4FAD-B91F-F5C1440A8548Q35995741-76B3C4E0-D4E9-4083-B232-FAC8E831F2C1Q37468664-1FFD2349-188F-4B22-924C-599A4C8D569FQ37702209-12C26D0E-40BA-48CA-8039-B51A1EECBD8AQ38306728-6704C0B7-64C0-426F-9A3F-C8F2BCB10C70Q39944286-7BDD4440-9351-455B-88DD-FDD8CEF0CE45Q40725974-6ADEE7F3-A952-4129-8C88-4EB4F45A5C66Q41893172-748A9A3C-DF19-46FD-ADBF-216B223EA47EQ41972480-86B73303-0257-4C5A-9053-0F463509DC07Q42005371-280B3522-D9D8-4710-A491-6CBD265AB116
P2860
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@ast
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@en
type
label
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@ast
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@en
prefLabel
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@ast
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@en
P2093
P1476
NF449, a novel picomolar potency antagonist at human P2X1 receptors.
@en
P2093
Fritz Markwardt
Günter Lambrecht
Günther Schmalzing
Martin Hülsmann
Matthias Kassack
Peter Nickel
P356
10.1016/S0014-2999(03)01761-8
P407
P577
2003-05-01T00:00:00Z